Monitoring Telotristat Ethyl Inhibition of Tryptophan Hydroxylase (TPH) in Neuroendocrine Tumors Using ?-[11C]Methyl-L-tryptophan (AMT)-PET
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
Price : $35 *
At a glance
- Drugs Telotristat etiprate (Primary)
- Indications Malignant carcinoid syndrome; Neuroendocrine tumours
- Focus Pharmacokinetics
- 08 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 Jun 2020.
- 08 Feb 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jun 2020.
- 08 Feb 2019 Status changed from not yet recruiting to recruiting.